Navigation Links
Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
Date:9/22/2010

WALTHAM, Mass., Sept. 22 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Sachs Biotech in Europe Investor Forum Wednesday, September 29, 2010 at the Radisson Blu hotel in Zurich, Switzerland.

Dr. Horobin will be a panelist on the Oncology Investment Panel at 12:00 pm CEST.  Her presentation will be given at 5:00 p.m. CEST and will include an overview of upcoming milestones including the ongoing phase 2 clinical program for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

The presentation will be available at Syndax's website, www.syndax.com.

About SyndaxSyndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.

Syndax holds rights to entinostat from Bayer Schering Pharma and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.Contact InformationJoanna Horobin, M.D.

Danielle Bertrand Syndax Pharmaceuticals, Inc.

WCG Tel: 781-419-1402

Tel: 415-946-1056 jhorobin@syndax.com

dbertrand@wcgworld.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
3. Access Pharmaceuticals, Inc. Signs $30M MuGard Supply Agreement With RHEI Pharmaceuticals HK LTD.
4. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
5. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
6. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
7. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
8. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
9. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
10. Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
11. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... EXTON, Pa. , Feb. 16, 2017 ... drugs, biologics, and medical devices, is pleased to announce ... Ph.D., has been selected as a winner of the ... SmartCEO Magazine and recognizes driven executives for ... undeniable work ethic. The awards ceremony and celebration is ...
(Date:2/16/2017)... YORK , Feb. 16, 2017 The ... reach USD 7.88 billion by 2021 from USD 5.49 ... On the basis of type, the preparative ... and preparative chromatography. In 2016, the process chromatography segment ... the global preparative and process chromatography. Growth in this ...
(Date:2/16/2017)... LOUIS , Feb. 16, 2017  Express Scripts (NASDAQ: ... of the World,s Most Admired Companies within the Health Care: Pharmacy ... be named one of the World,s Most Admired Companies," said ... driven by the commitment and passion of our 26,000 employees to ... we serve." ...
Breaking Medicine Technology:
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... tools that allow for the electronic prescribing of controlled and non-controlled substances plus ... Ninety percent of pharmacies in the United States now accept electronic prescriptions, according ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – ... reimbursement questions manufacturers should be asking before selecting an FDA approval pathway? ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... announced today that Karen Pilley has been promoted to Chief Executive Officer. ... shifting healthcare paradigm – a shift that demands the transition from pay-for-service to ...
Breaking Medicine News(10 mins):